Free Trial
NASDAQ:ALIM

Alimera Sciences (ALIM) Stock Price, News & Analysis

$2.95
-0.04 (-1.34%)
(As of 05/24/2024 ET)
Today's Range
$2.93
$3.11
50-Day Range
$2.95
$4.05
52-Week Range
$2.46
$4.38
Volume
82,138 shs
Average Volume
60,967 shs
Market Capitalization
$154.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Alimera Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
171.2% Upside
$8.00 Price Target
Short Interest
Healthy
0.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of Alimera Sciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.13) to $0.21 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.68 out of 5 stars

Medical Sector

404th out of 917 stocks

Pharmaceutical Preparations Industry

180th out of 427 stocks

ALIM stock logo

About Alimera Sciences Stock (NASDAQ:ALIM)

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

ALIM Stock Price History

ALIM Stock News Headlines

Alimera Sciences Reports First Quarter 2024 Results
Luckie & Company Acquires Marbury Creative Group
Luckie & Co. acquires Atlanta marketing agency
Q4 2023 Alimera Sciences Inc Earnings Call
See More Headlines
Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2024
Today
5/25/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALIM
Employees
154
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$10.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+171.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-20,130,000.00
Pretax Margin
-23.68%

Debt

Sales & Book Value

Annual Sales
$80.75 million
Book Value
$0.78 per share

Miscellaneous

Free Float
35,939,000
Market Cap
$154.55 million
Optionable
Optionable
Beta
1.20

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Richard S. Eiswirth Jr.Mr. Richard S. Eiswirth Jr. (Age 56)
    CEO & Director
    Comp: $597.87k
  • Mr. David R. Holland (Age 60)
    Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets
    Comp: $413.5k
  • Dr. Philip Ashman Ph.D. (Age 59)
    President of International Operations
    Comp: $389.86k
  • Mr. Todd Michael Wood (Age 54)
    President of U.S. Operations
  • Mr. Elliot Maltz CPA (Age 39)
    CFO & Treasurer
  • Mr. Jason Werner
    Chief Operating Officer
  • Christopher S. Visick
    VP, General Counsel & Secretary
  • Dr. David Dyer M.D.
    Chief Retina Specialist

ALIM Stock Analysis - Frequently Asked Questions

Should I buy or sell Alimera Sciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings
or view top-rated stocks.

What is Alimera Sciences' stock price target for 2024?

3 equities research analysts have issued 1-year target prices for Alimera Sciences' shares. Their ALIM share price targets range from $6.00 to $10.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 171.2% from the stock's current price.
View analysts price targets for ALIM
or view top-rated stocks among Wall Street analysts.

How have ALIM shares performed in 2024?

Alimera Sciences' stock was trading at $4.32 at the beginning of the year. Since then, ALIM shares have decreased by 31.7% and is now trading at $2.95.
View the best growth stocks for 2024 here
.

When is Alimera Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our ALIM earnings forecast
.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) posted its quarterly earnings data on Tuesday, May, 14th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.08. The biopharmaceutical company earned $23.01 million during the quarter, compared to analyst estimates of $23.72 million. Alimera Sciences had a negative net margin of 23.74% and a negative trailing twelve-month return on equity of 53.49%. During the same quarter in the previous year, the business posted ($0.71) earnings per share.

When did Alimera Sciences' stock split?

Alimera Sciences's stock reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What guidance has Alimera Sciences issued on next quarter's earnings?

Alimera Sciences issued an update on its FY 2024 earnings guidance on Tuesday, May, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $105.0 million-, compared to the consensus revenue estimate of $103.8 million.

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.00%), Ancora Advisors LLC (0.45%), Hillsdale Investment Management Inc. (0.08%), Fifth Lane Capital LP (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam Morgan, Alto Investors Lp Palo, Caligan Partners Lp, James R Largent, John Philip Jones, Richard S Eiswirth Jr and Stanley Morgan.
View institutional ownership trends
.

How do I buy shares of Alimera Sciences?

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALIM) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners